Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 31.05
- Piotroski Score 4.00
- Grade Buy
- Symbol (RXST)
- Company RxSight, Inc.
- Price $45.10
- Changes Percentage (0.65%)
- Change $0.29
- Day Low $44.63
- Day High $45.85
- Year High $66.54
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/26/2025
- Fiscal Year End N/A
- Average Stock Price Target $67.00
- High Stock Price Target $110.00
- Low Stock Price Target $52.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.24
- Trailing P/E Ratio -46.15
- Forward P/E Ratio -46.15
- P/E Growth -46.15
- Net Income $-48,608,000
Income Statement
Quarterly
Annual
Latest News of RXST
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
RxSight, Inc. (NASDAQ:RXST) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
RxSight, Inc. recently reported Q3 results, with shares down 6%. Despite meeting revenue expectations, losses per share were lower than predicted. Analysts forecast a 47% revenue increase in 2025 and ...
By Yahoo! Finance | 1 week ago -
RxSight, Inc. (RXST): Top Investors Are Investing In This Small-Cap Stock Now
A recent analysis compares RxSight, Inc. (NASDAQ:RXST) with other small-cap stocks, highlighting its advancements and growth prospects in the cataract surgery market. Wall Street predicts positive com...
By Yahoo! Finance | 1 month ago -
Institutional investors control 71% of RxSight, Inc. (NASDAQ:RXST) and were rewarded last week after stock increased 6.0%
Institutions hold a 71% stake in RxSight, giving them significant influence over its share price. With a market cap of US$2.3b, institutional investors have benefited from the company's growth....
By Yahoo! Finance | 4 months ago
